Loading company…
PreciseDx uses AI-based tissue analysis to provide cancer risk information and support treatment decisions.
Founded in 2020 and based in New York, PreciseDx develops AI-based cancer risk stratification tools using tissue morphology and clinical data. Its products include breast and prostate tests. The company was founded by Jack Zeineh, Gerardo Fernandez, Michael Donovan, and Carlos Cordon-Cardo; Wayne Brinster is CEO. In June 2025, it raised USD 11 million from Philips Health Technology Ventures, Eventide Asset Management, Merck Global Health Innovation Fund, LabCorp Ventures, Quest Diagnostics, GenHenn Capital, and others to expand clinical data collection and prepare for a 2026 PreciseBreast launch.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in